Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Ophthotech and Nivalis slash jobs
by Ann M. Thayer
January 23, 2017
| A version of this story appeared in
Volume 95, Issue 4
Poor clinical trial results have pushed two companies to each cut about 80% of their staff, including top executives, as they determine how to move ahead. In December, Ophthotech reported that its anti-PDGF therapy Fovista failed to show any benefit in two late-stage macular degeneration trials. At the time, the company had about 154 employees. Separately, Nivalis Therapeutics is restructuring and will retain just five of its 30 employees after a disappointing Phase II trial of its cystic fibrosis drug cavosonstat.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter